Imricor (IMR) is held by 2 ASX ETFs. Over the last year it fell 6.4%: on $10,000, −$644. We explain 9 big moves in that time.
About IMR
- SectorHealth Care
- IndustryHealth Care Equipment & Services
- Size$520.0m
- Held by2 ETFs
- Big moves9 in 1Y
Each dot is a move we explain. Tap one, or a row of Why it moved, to see what caused it.
Why it moved
- +3.1%peak +6.7%18 Sep 2026· Regulatory
Imricor Medical Systems rose as investor interest built ahead of an anticipated US regulatory approval, supported by a new securities quotation filing that signals a recent capital raise settling into the market.
- −0.5%peak +2.4%14 Aug 2026· Regulatory
Imricor Medical Systems rose after news it submitted its final 510(k) devices, bringing its full US FDA product platform closer to regulatory clearance.
- +5.1%13 Aug 2026· Contract
Imricor Medical Systems submitted final 510(k) devices, moving its full US FDA product platform closer to commercialization.
- +12.5%2 Jul 2026· Regulatory
Imricor Medical Systems jumped after receiving FDA paediatric clearances for its NorthStar and diagnostic catheter, advancing its U.S. commercialisation strategy.
- +5.4%25 Mar 2026· Unknown
Insufficient evidence to determine the cause of the abnormal price movement.
- −5.8%16 Mar 2026· Unknown
Insufficient evidence to determine the cause of the price move.
- +10.5%29 Jan 2026· Regulatory
FDA cleared Imricor's NorthStar Mapping System, driving a sharp rally and re-rating.
- +17.1%12 Jan 2026· Regulatory
FDA approval for Imricor Medical ignited a sharp rally in its shares, driving an 8.5x multiple of the normal daily range.
- +12.1%4 Nov 2025· Contract
Imricor announced the first-in-human ischemic VT ablation successfully performed in iCMR, a major clinical milestone.
Held by 2 ETFs
Of every $10,000 in each fund, how much is in IMR today.
Why did IMR rise 10.5% on 29 Jan 2026?
Imricor
FDA cleared Imricor's NorthStar Mapping System, driving a sharp rally and re-rating.
Multiple news articles on Jan 29, 2026, directly attribute the stock's jump to FDA approval of NorthStar Mapping System, which is a clear regulatory milestone. The price move occurred on Jan 28, with follow-on coverage confirming the cause, and the magnitude is consistent with a significant regulatory catalyst.
Written by a language model from the evidence below, and it can be wrong. Tell us and we will fix or remove it. General information only, not financial product advice. It does not consider your objectives, finances or needs. Past performance is not a guide to future performance.
Evidence
News coverage
What it did to the 2 ETFs holding IMR
On $10,000 in each fund, at the weight it holds today